Skip to content 
OUR MAMS PLATFORM TRIALS
The DECODE-PD group has two MAMS platform trials; SLEIPNIR and HYDRA.
To read more about them, click below. To understand what are MAMS platform trials, scroll down below.
SLEIPNIR is a pioneering platform designed to test multiple compounds for target engagement in parallel, advancing only the most promising candidates to HYDRA.
HYDRA is a phase III trial platform that will investigate whether candidate treatments that pass testing at SLEIPNIR can slow or stop the progression of Parkinson’s disease.
WHAT ARE MULTI-ARM MULTI-STAGE (MAMS) PLATFORM TRIALS?
MAMS platform trials is a flexible and adaptive approach that allow multiple treatments, with the same route of administration, to be tested simultaneously against a single control. It allows stopping treatments that don’t seem promising (futile arms), while new ones are included. In addition, participants can be moved between arms after a wash-out period (time required to exclude the influence of the previous treatment), strengthening the potential of the most promising interventions.
ADVANTAGES OF MAMS STUDIES
FLEXIBILITY
Multiple treatments tested simultaneously, allowing early detection of ineffective arms and their replacement for promising interventions.
ANSWER MULTI QUESTIONS
Answer multi questions under a single trial and regulatory framework, rather than answering them separately in different trials, as in traditional designs.
LESS PATIENTS
Reduces the number of patients treated at ineffective arms while it maximises the number of participants on more efficient treatments.
FASTER AND LESS COSTLY
With no need to set up an entire new clinical trial for each new intervention, MAMS trials are faster and less costly.
